BioRN Leads InnoLife Consortium to Success in the Competition Healthy Living and Active Ageing of the EIT
BioRN is a member of the consortium InnoLife, which has won the call for the Knowledge and Innovation Community (KIC) Healthy Living and Active Ageing (EIT Health) of the European Institute for Innovation and Technology (EIT). With a grant volume of up to €700 million and a total project volume of more than €2 billion, this is one of the largest publicly funded initiatives in the health sector worldwide.
Among the 50 core partners and additional 90 associate organisations from nine EU countries are, among others, Roche Diagnostics in Mannheim, AbbVie in Ludwigshafen and the University of Heidelberg as representatives of the BioRN cluster as well as major institutions and companies from the BioRN partner regions Cambridge in the United Kingdom and Leuven in Belgium (Health Axis Europe Alliance). In the next 7 years the consortium partners will cooperate as a Knowledge and Innovation Community (KIC) with the aim of delivering innovative products, services and concepts that will improve quality of life and contribute to the sustainability of healthcare across Europe. During the application phase the German partners of the consortium, including the BioRN cluster in Heidelberg as well as the top regions BioM in Munich, Medical Valley in Erlangen and BIO.NRW with its locations in Cologne and Aachen, had already agreed that the EIT Health projects would be coordinated from Heidelberg.
BioRN managing director Dr Christian Tidona made the following statement on winning the KIC call: “The successful initiation of this worldwide unique large-scale project is the direct result of the investment of the German Federal Government, the State of Baden-Württemberg and the regional partners in our BioRN leading-edge cluster. This opportunity for internationalization and active participation from major local institutions and companies in the health sector will sustainably strengthen our Rhine-Neckar metropolitan region.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.